Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

47.36
-2.9400-5.84%
Post-market: 47.360.00000.00%16:38 EDT
Volume:992.11K
Turnover:47.74M
Market Cap:1.97B
PE:-15.41
High:49.62
Open:48.89
Low:46.78
Close:50.30
Loading ...

Tarsus Pharmaceuticals: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating

TIPRANKS
·
Yesterday

Tarsus Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
Yesterday

Stock Track | Tarsus Pharmaceuticals (TARS) Plunges 7.95% Pre-Market Despite Beating Q1 Earnings Estimates

Stock Track
·
02 May

Tarsus Pharmaceuticals Inc (TARS) Q1 2025 Earnings Call Highlights: Record Sales Surge and ...

GuruFocus.com
·
02 May

Tarsus Pharmaceuticals Reports Strong Q1 2025 Growth

TIPRANKS
·
02 May

Tarsus Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
02 May

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates

Zacks
·
02 May

Tarsus Pharmaceuticals Q1 EPS $(0.64) Beats $(0.76) Estimate, Sales $78.33M Beat $72.47M Estimate

Benzinga
·
02 May

BRIEF-Tarsus Pharmaceuticals Q1 Net Income USD -25.12 Million Vs. IBES Estimate USD -25.1 Million

Reuters
·
02 May

Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements

THOMSON REUTERS
·
02 May

Press Release: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements

Dow Jones
·
02 May

Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?

Zacks
·
30 Apr

Tarsus Pharmaceuticals to present abstracts on XDEMVY at ASCRS meeting

TIPRANKS
·
22 Apr

Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting

GlobeNewswire
·
22 Apr

Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

Business Wire
·
22 Apr

With Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) It Looks Like You'll Get What You Pay For

Simply Wall St.
·
02 Apr

Oppenheimer Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
28 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTx

Reuters
·
13 Mar

Sector Update: Health Care Stocks Flat to Lower Premarket Thursday

MT Newswires Live
·
13 Mar

BUZZ-Tarsus Pharma dips after upsized $125 mln stock offering

Reuters
·
13 Mar